Associate Professor Barbara Kemp-Harper co-leads the Cardiovascular & Pulmonary Pharmacology Group in the Department of Pharmacology at Monash University. Her research aims to identify novel therapeutic strategies for the prevention and treatment of diseases such as systemic and pulmonary hypertension. She is particularly interested in harnessing the protective nitric oxide/cGMP signalling pathway together with targeting the upregulated immune system to more effectively treat these conditions.
Barbara is internationally recognised for her work on nitroxyl, a novel sibling of nitric oxide, which has many advantages over nitric oxide. Barbara’s work has identified a potential for nitroxyl-like drugs to be used in the treatment of angina, high blood pressure and high cholesterol. Her recent research program focuses on the role of the innate immune system in the pathophysiology of systemic and pulmonary hypertension, exploring the therapeutic utility of targeting the chemokine, CCL18 and NLRP3 inflammasome-derived cytokines in the treatment of these diseases.